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ABSTRACT
In this article, we have developed novel data visualization tools and
a Theta comparative cell scoring (TCCS) method, which supports
high-throughput in vitro pharmacogenomic studies across diverse
cellular phenotypes measured by multiparametric high-content
analysis. The TCCS method provides a univariate descriptor of di-
vergent compound-induced phenotypic responses between distinct
cell types, which can be used for correlation with genetic, epige-
netic, and proteomic datasets to support the identification of
biomarkers and further elucidate drug mechanism-of-action.
Application of these methods to compound profiling across high-
content assays incorporating well-characterized cells representing
known molecular subtypes of disease supports the development of
personalized healthcare strategies without prior knowledge of a
drug target. We present proof-of-principle data quantifying distinct
phenotypic response between eight breast cancer cells representing
four disease subclasses. Application of the TCCS method together
with new advances in next-generation sequencing, induced plu-
ripotent stem cell technology, gene editing, and high-content
phenotypic screening are well placed to advance the identification
of predictive biomarkers and personalized medicine approaches
across a broader range of disease types and therapeutic classes.
INTRODUCTION
T
he treatment of complex disease in human popula-
tions is often confounded by the broad heterogeneity
in the mechanisms responsible for the generation and
evolution of disease-affected cells. Within an indi-
vidual patient and between genetically distinct patients, such
heterogeneity in disease mechanisms contributes to poor drug
responses and relapses observed in the clinic.1,2 Sequencing of
the human genome and advances in characterizing patient
disease at genetic and proteomic levels support the personal-
ized medicine concept of treating each individual patient with
the most appropriate therapy for their disease.3,4
Key to the personalized medicine approach is the identifi-
cation of biomarkers, which can be readily measured in patient
samples to predict drug response. Many such biomarkers, for
example, BRAF V600E (Melanoma/Colorectal Cancer); EGFR
(Nonsmall cell lung carcinoma); and HER-2 (Breast Cancer), are
associatedwithmonitoring activation state andmutation status
of known drug targets to predict response to therapy.5–7 Thus,
the personalized medicine approach is well suited to target-
directed drug discovery strategies where target pathways are
clearly defined. However, such target-directed personalized
medicine strategies are unsuitable for many complex diseases
and drugs discovered by phenotypic drug discovery, where they
are not defined by a single target or the mechanism-of-action
and therapeutic targets remain to be fully elucidated.8,9 Thus,
more unbiased approaches to the identification of biomarkers,
including genetic or pathway signatures, which predict drug
response are required to expand the personalized medicine
concept across complex disease types and therapeutic classes.
Comparative analysis of well-characterized panels of human
cell lines derived from distinct individuals has many applica-
tions in basic research, drug discovery, and personalized med-
icine. Genomic and transcriptional profiling of cancer cell line
panels, such as the National Cancer Institute 60 human tumor
cell line drug screen collection, provide a genetic context to
comparison of cell function and drug sensitivity, supporting
biomarker discovery and drugmechanism-of-action analysis.10
High-throughput in vitro pharmacogenomic studies
across larger cancer cell line panels have been established
and provide valuable resources, such as the Cancer Cell
Line Encyclopedia (CCLE) from the Broad Institute www
.broadinstitute.org/ccle/home and the Catalogue of Somatic
Mutation in Cancer Cell Lines project from the Sanger In-
stitute http://cancer.sanger.ac.uk/cell_lines, which facilitate
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pharmacogenomic analysis. Such drug sensitivity profiling
across genetically defined cell panels is now routinely im-
plemented in academia and industry to identify biomarkers
of response to support disease positioning and patient stratifi-
cation strategies, or to further understand drug mechanism-of-
action at genetic and proteomic levels.11,12
To our knowledge, all examples of in vitro high-throughput
pharmacogenomic studies carried out to date utilize either a
concentration of a drug that gives half-maximal response (EC50)
or concentration of a drug that gives half-maximal inhibition of
cell proliferation (GI50) value obtained by standard cell viability
assays as the primary phenotypic endpoint for correlating drug
sensitivity with genomic or transcriptomic datasets. While the
GI50 and EC50 measurements of cell viability provide the nec-
essary univariate value for quantifying drug sensitivity across a
panel of cell lines, this method has several limitations.
Accurate measurement of EC50 or GI50 values is dependent
upon obtaining full sigmoidal dose–response curves for each
drug or compound tested in the assay. Dose–response curves
and thus the EC50/GI50 calculations are prone to fluctuation
dependent upon assay conditions, including cell culture me-
dia, atmospheric conditions, cell line health and cell line batch
variation, and the type of viability assay reagents used. In-
deed, comparative analysis of large pharmacogenomic studies
published by the Broad and Sanger institutes have resulted in
reports of inconsistency between the genetic signatures of
drug sensitivity assigned to drugs shared between both stud-
ies.13,14 Cell viability assays and EC50/GI50 values are also not
suitable for the majority of disease models, which are not
defined by a single viability endpoint, or for quantifying drug
response in more complex and physiologically relevant cell
assays such as three-dimensional (3D) coculture models.
High-content imaging enables the quantification of multiple
phenotypic cellular endpoints with high spatial and temporal
resolution supporting drug sensitivity testing across more
complex in vitro assays including 3D and coculture models.15
Image-based phenotypic profiling combined with multi-
parametric analysismethods allows detailed characterization of
drug mechanism-of-action and classification of phenotypic
response, including identification of novel compound target
associations based upon similarity of multiparametric pheno-
typic fingerprintswith annotated reference compound sets.16–22
The application of multiparametric biological profiling of com-
pound libraries, by image-informatics and biospectra analysis
methods, supports unbiased approaches to mechanism-of-action
classification and identification of structure–activity relationships
independent of target hypothesis.23–25 While multiparametric
methods incorporating machine learning and artificial neural net-
works have steadily evolved to support phenotypic profiling across
several cell types,18,20,26 there are few studies that perform com-
parative multiparametric phenotypic analysis between distinct cell
types in drug discovery. Thus, despite over 15 years of continued
development in the high-content screening field, there are
few reports of pharmacogenomic studies performed across
the diversity of complex phenotypes that can be measured
by multiparametric high-content analysis approaches. A
number of challenges that must be overcome to apply high-
content phenotypic profiling to pharmacogenomic or phar-
macoproteomic strategies include the following: defining
relevant phenotypic endpoints, which appropriately quantify
drug sensitivity; quantifying diverse phenotypic response
across a dose response; visualizing multiple diverse pheno-
types elicited across dose response and distinct cell panels;
and reducing multiparametric high-content analysis of cell
phenotype to a robust univariate metric for correlating drug
sensitivity with genomic or proteomic datasets.
The goals of this study were to develop a robust and scalable
method for quantifying diverse multiparametric high-content
phenotypes and distinct compound-induced phenotypic re-
sponseacross apanelof cell lines.Wedescribe theoptimizationof
a high-content cell-painting assay to enable analysis of a broad
range of cell phenotypes across a panel of clinically relevant
breast cancer subtypes.We present newmethods for normalizing
and displaying distinct and dose-dependent multiparametric
high-content phenotypic response across multiple cell types. We
introduce the development and application of the ‘‘Theta Com-
parative Cell Scoring’’ (TCCS) method for calculating distinct
phenotypic response between cell types. We describe the broad
utility of the TCCS method in providing a univariate metric for
quantifying distinct phenotypic response between compounds
tested in the same cell and for compounds tested across multiple
cell types. We make available the source code to enable appli-
cation of TCCS across large high-content datasets. We present
proof-of-principledata fromasmall compoundscreenperformed
on a panel of eight breast cancer cells representing four well-
characterized and clinically relevant subtypes. We demonstrate
the ability of our TCCS method to cluster cell types, which have
similar or distinct phenotypic response to individual compounds,
to guide patient stratification hypothesis and facilitate pharma-
cogenomic or proteomic studies.We discuss the potential impact
of this approach upon extending the application of in vitro
pharmacogenomic and personalized medicine strategies across a
wider range of disease areas and therapeutic classes.
MATERIALS AND METHODS
Cell Culture
Eight breast cancer cell lines were selected for their strati-
fication of four well-characterized breast cancer clinical
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subtypes (Table 1). Authenticated cell lines were acquired
from the American Type Culture Collection and carefully
monitored for morphological changes to ensure authenticity.
Cell lines were cultured in either Dulbecco’s Modified Eagle’s
Medium (HCC1954, MCF7, KPL4, MDA-MB-231, MDA-MB-
157, and SKBR3) or Roswell Park Memorial Institute-1640
(HCC1569 and T47D) supplemented with 10% fetal bovine
serum and 2mM L-glutamine and incubated at 37C, 5% CO2.
Two thousand five hundred cells were seeded into each of the
inner 60 wells of 96-well plates (#165305; Thermo) in 100 mL
media and incubated for 24 h before compound treatment.
Outer wells of plates were filled with 100 mL phosphate-
buffered saline (PBS).
Compound Treatment
A panel of well-annotated compounds purchased from
commercial suppliers (Table 2) were prepared as 10mM stock
solutions in dimethyl sulfoxide (DMSO). 1,000· compound
plates were then created with semi-log dilutions in DMSO.
Each plate contained six wells of 0.1% DMSO as a negative
control and six wells of 200 nM staurosporine as a positive
control. Following compound addition, cell assay plates were
incubated at 37C, in 5% CO2 incubator for an additional 48 h
before fixation, staining, and high-content imaging.
Imaging
We adapted the cell painting protocol from Gustafsdottir
et al.27 to optimize the cell staining across the eight selected
breast cancer cell lines. Specific modifications to the original
protocol by Gustafsdottir et al.27 were implemented to cir-
cumvent morphological changes induced upon the MDA-MB-
231 cell line, which was particularly sensitive to live cell
staining. The modifications included using all stains on
postfixed samples and adjusting concentrations of reagents to
optimize staining across the cell lines. The following adapted
cell painting protocol was therefore applied to our breast
cancer cell panel.
After a 48-h incubation in the presence of compounds, an
equal volume of 8% paraformaldehyde (PFA) was added to the
culture media of each well resulting in a final concentration of
4% PFA fixation buffer; the plates were then incubated at
room temperature for 20min, followed by three washes in
100 mL PBS. Permeabilization was performed with the addi-
tion of 50 mL 0.1% Triton-X100 to each well and incubation at
room temperature for 20min followed by three washes in
100 mL PBS.
The staining solution was prepared in a blocking buffer
consisting of 1% bovine serum albumin in PBS (Table 3).
Thirty microliters of staining solution was added to each well
and incubated in darkness at room temperature for 30min
followed by three washes in 100 mL PBS, with no final aspi-
ration. Plates were then sealed (#PCR-SQ plate max) and im-
aged immediately.
Plates were imaged on a Molecular Devices ImageXpress
Micro XLS, six fields of view were captured per well using
a 20· objective and five filters, DAPI (387/447 nm), FITC
(482/536 nm), Cy3 (531/593 nm), TxRed (562/642 nm), and
Cy5 (628/692 nm). Exposure, binning, and other image
settings were not altered between cell lines.
Image Analysis
Images were analyzed using CellProfiler v2.1.119 to extract
309 features (Supplementary Table S1; SupplementaryData are
available online at www.liebertpub.com/adt). Briefly, cell nu-
clei were segmented from the nuclei image based on intensity
and shape, and used as seeds to segment cell areas in the other
channels. Subcellular structures such as nucleoli and endo-
plasmic reticulum speckles were segmented and assigned to
parent objects. From these objects, measurements such as size,
shape, and spatial distribution were measured. The final Cell-
Profiler settings applied in this studywere created by iteratively
adjusting the parameters and assessing the performance of cell
segmentation by eye acrossmultiple drug treatments for all cell
types under evaluation, to ensure themost robust segmentation
Table 1. Panel of Breast Cancer Cell Lines
Mutation Status
Cell Line Subclass PTENa PI3Kb
MCF7 ERc WTd E545K
T47D ER WT H1047R
MDA-MB-231 TNe WT WT
MDA-MB-157 TN WT WT
HCC1569 HER2f WT WT
SKBR3 HER2 WT WT
HCC1954 HER2 ?g H1047R
KPL4 HER2 ? H1047R
aPhosphatase and tensin homolog.
bPhosphoinsitide-3-kinase.
cEstrogen receptor.
dWild type.
eTriple negative.
fHuman epidermal growth factor receptor 2.
gLack of consensus regarding the mutational status of those cell lines.
ER, estrogen receptor; HER2, human epidermal growth factor; PI3K,
phosphoinositide 3-kinase; PTEN, phosphatase and tensin homolog; TN, triple
negative; WT, wild type.
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for each distinct cell type, and drug-induced phenotype is
achieved.
Data Preprocessing
Out of focus and low-quality images were detected and
removed by filtering on saturation and focus measurements
provided in the CellProfiler output. Image averages of single
object measurements from CellProfiler were aggregated
by taking the median of each measured feature per image.
Features were normalized and
standardized on a plate-by-plate
basis by dividing each feature by
the median DMSO response for
that feature and then scaled by a
z-score to have a mean of 0 and a
standard deviation of 1. Feature
selection was performed by cal-
culating pair-wise correlations of
features and removing one of a
pair of features that have corre-
lation greater than 0.9 and re-
moving features with very low or
zero variance, using the findCor-
relation and nearZeroVar func-
tions in the caret R package.28
Quantifying Differential
Morphological Responses
by TCCS
Principal component analysis
(PCA) was performed and the data
were then centralized to the DMSO
centroid. This was carried out by
calculating the mean of principal
component (PC) 1 and 2 for the
DMSO subset of the data, and then
subtracting this from the PC values.
With each data point as a vector
in two-dimensional (2D) space
formed by the first two PCs, the
normof eachvectorwas calculated,
returning a Euclidean distance of
each data point from the DMSO
centroid. Then, the angles between
each vector and a reference vector
(0, 1) were calculated and denoted
as theta (y). The reference vector is
arbitrarily set as a vector along the
x-axis and enables easy compari-
son between the polar coordinate histograms of the PCA biplot in
Cartesian coordinates. For replicates, median values of PCs were
calculated before calculating vectors; this simple approach
avoids the pitfalls in calculating themean of circular quantities—
for example the arithmetic mean of 1 and 359 is 180, despite
the close proximity of the values in polar coordinates.
As any perturbations that do not produce morphologi-
cal changes will be indistinguishable from negative control
values, these points were found clustered within the negative
Table 2. Compounds
Compound Class Sub-Class Supplier Cat. No.
Paclitaxel Microtubule disrupting Microtubule stabilizer Sigma T7402
Epothilone B Microtubule disrupting Microtubule stabilizer Selleckchem S1364
Colchicine Microtubule disrupting Microtubule destabilizer Sigma C9754
Nocodazole Microtubule disrupting Microtubule destabilizer Sigma M1404
Monastrol Microtubule disrupting Eg5 kinesin inhibitor Sigma M8515
ARQ621 Microtubule disrupting Eg5 kinesin inhibitor Selleckchem S7355
Barasertib Microtubule disrupting Aurora B inhibitor Selleckchem S1147
ZM447439 Microtubule disrupting Aurora B inhibitor Selleckchem S1103
Cytochalasin D Actin disrupting Actin disrupter Sigma C8273
Cytochalasin B Actin disrupting Actin disrupter Sigma C6762
Jasplakinolide Actin disrupting Actin stabilizer Tocris 2792
Latrunculin B Actin disrupting Actin stabilizer Sigma L5288
MG132 Protein degradation Proteosome Selleckchem S2619
Lactacystin Protein degradation Proteosome Tocris 2267
ALLN Protein degradation Cysteine/calpain Sigma A6165
ALLM Protein degradation Cysteine/calpain Sigma A6060
Emetine Protein synthesis Protein synthesis Sigma E2375
Cycloheximide Protein synthesis Protein synthesis Sigma 1810
Dasatinib Kinase inhibitor Src-EMT Selleckchem S1021
Saracatinib Kinase inhibitor Src-EMT Selleckchem S1006
Lovastatin Statin Statin Sigma PHR1285
Simvastatin Statin Statin Sigma PHR1438
Camptothecin DNA damaging agent Topoisomerase 1 inhibitor Selleckchem S1288
SN38 DNA damaging agent Topoisomerase 1 inhibitor Selleckchem S4908
Src-EMT, Src kinase and Epithelial-Mesenchymal Transition inhibitor.
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control cloud in a scatter-plot of the first two PCs. As these
compounds are centered on the origin (0, 0), the angles cal-
culated from their vectors are uniformly distributed in all
directions and meaningless as a phenotypic direction. There-
fore, a minimum distance from the DMSO centroid was de-
termined as 1 standard deviation of the vector distances from
the origin, and compounds within this distance were defined
as inactive in our assay and not used in further calculations.
Active compounds were only included if they fell beyond this
minimum limit for all the eight cell lines.
To calculate the phenotypic difference between compounds
tested within the same cell line or a compound tested across
different cell lines using the vector analysis described above,
the absolute difference between the two theta values can be
used. However, as any difference greater than 180 and ap-
proaching 360 starts to reflect morphologies becoming more
similar, the absolute difference values have to be constrained
between 0 and 180; this is carried out for values greater
than 180 by subtracting the value from 360, for example, 190
will become 170. We named the method ‘‘Theta-Comparative–
Cell-Scoring’’ to reflect the use of vectors applied to multi-
parametric high-content data to quantify distinct phenotypic
response between cell types.
Data and Code Availability
The CellProfiler pipelines, numeric data, and R code to
run the analyses and generate the figures are available at
github.com/swarchal/TCCS_paper
RESULTS
High-Content Phenotypic Comparisons Between
Morphologically Distinct Breast Cancer Cell Subtypes
We havemodified the cell painting assay previously applied
to the osteosarcoma cell line U2OS cells27 to a panel of breast
cancer cell lines representing clini-
cally relevant subtypes. Eight breast
cancer cell lines representing four
pairs for each of the following
clinical subtypes: estrogen receptor
(ER)-positive, triple negative, human
epidermal growth factor receptor 2
(Her2)-postive/Phosphatase and
tensin homolog (PTEN) and phos-
phoinositide 3-kinase (PI3K) wild
type, and Her2-positive/PTEN and
PI3Kmut were selected for this
study (Table 1).
The modified cell painting as-
say was optimized to enable the CellProfiler image analysis
software to segment individual cells for each well and extract
features, which provide detailed morphological analysis of
individual breast cancer cell phenotypes. Representative im-
ages of the eight breast cancer cells stained with the modified
cell-painting protocol are displayed in three channels in
Figure 1A and respective cell segmentation masks generated
by CellProfiler analysis are shown in Figure 1B. As the breast
cancer cell lines look inherently different from one another
(Fig. 1), detecting differential phenotypic changes between
them requires normalization against the negative control
phenotype for each cell line. This was performed by dividing
each feature by the median DMSO value for that feature on a
plate-by-plate basis followed by z-scoring each feature indi-
vidually for all cell lines. Normalization in this manner
achieved two objectives: (1) removing any batch effects that
may be present across plates and (2) normalizing all pheno-
typic measurements as standardized fold changes from the
negative control values per cell line. PCA was then performed
on the normalized dataset of all cell lines using the prcomp
function in R.
Quantifying Differential Morphological Response
Between Cell Lines to the Same Compound
When the first two PCs are visualized as a 2D scatter plot,
low concentrations of compounds are typically found near or
within the DMSO cluster. However, with increasing concen-
trations, the points are often seen to proceed toward a given
trajectory, describing decreasing phenotypic similarity to the
negative control cells with increasing compound concentra-
tion. In the case of MDA-MB-231 cells treated with Cyclo-
heximide and Barasertib, the compounds result in trajectories
with opposing directions, describing opposite morphological
changes (Fig. 2). The case of Barasertib and Cycloheximide
provide a proof-of-principal example in the ability of the
Table 3. Stains and Concentrations Used in the Modified Cell-Painting Protocol
Stain Structure Labeled
Wavelength
(ex/em [nm]) Concentration Cat. No.; Supplier
Hoechst 33342 Nuclei 387/447 2mg/mL #H1399; Mol. Probes
SYTO14 Nucleoli 531/593 3 mM #S7576; Invitrogen
Phalloidin 594 F-actin 562/624 0.85 U/mL #A12381; Invitrogen
Wheat germ
agglutinin 594
Golgi and plasma
membrane
562/624 8 mg/mL #W11262; Invitrogen
Concanavalin A 488 Endoplasmic reticulum 462/520 11mg/mL #C11252; Invitrogen
MitoTracker DeepRed Mitochondria 628/692 600 nM #M22426; Invitrogen
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method described to distinguish opposing phenotypes re-
presented by enlarged and aneuploidy nuclei characteristic of
cytokinesis defects elicited by inhibitors of Aurora kinase B
(Barasertib) in contrast to the condensed nuclei characteristic
of the protein synthesis inhibitor (Cycloheximide).
These distinct phenotypic trajectories have been quantified
as theta values against a reference vector using Equation (1),
where u is the PC1, PC2 vector, and v is the reference vector of
(0, 1) (Fig. 2). A circular histogram of the theta values can then
be plotted to visualize the distribution of compound induced
phenotypes. The circular histogram theta plots provide an in-
tuitive indication of a phenotypic direction produced by a
specific pharmacological perturbation, as well as any change in
phenotypic direction across increasing concentrations thatmay
indicate off-target effects.Figure 3A shows a circular histogram
of the data pooled from all eight cell lines treated with an eight-
point half-log dose response of the Aurora B kinase inhibitor
Barasertib. Using the same directional histograms, data can also
be split by cell lines to directly visualize differential phenotypic
response across a panel of distinct cell lines (Fig. 3B).
The difference in theta values between cell lines can then be
calculated for a given compound to provide a univariate theta
metric of phenotypic dissimilarity between cell types (Fig. 3C).
It is possible to rank similarity and dissimilarity of each
compound-induced phenotype between cells or between other
compounds on a scale of 0–180 where 0 describes the most
similar phenotypes and 180 the most dissimilar phenotypes.
We name this method ‘‘Theta Comparative Cell Scoring’’ and
provide the formula below:
h = cos
u  v
jjujjvjj
 
·
180
p
ð1Þ
Screening for Differential Phenotypic Response
Across the Panel of Breast Cancer Subtypes
To evaluate the TCCS method for the ability to identify
compounds that induce differential phenotypic responses
between the breast cancer cell lines, we calculated the differ-
ence between theta values for all eight breast cancer cell lines
treated with 1 mM of 24 different compounds. Compounds
Fig. 1. Cell painting assay applied to eight distinct breast cancer cell lines. (A) Composite image of cell lines treated with 0.1% DMSO.
Channels used: Red—MitoTracker DeepRed (mitochondria); Green—Concanavalin A (endoplasmic reticulum); Blue—Hoechst33342 (nu-
clei). Scale bars: 100 mm. (B) Image masks from CellProfiler showing nuclei and cell body segmentation. DMSO, dimethyl sulfoxide.
Fig. 2. Phenotypic directions in the first two PCs. Scatter plot of
the first two PCs of MDA-MB-231 cells treated with a small com-
pound library. Principal component analysis was carried out on 309
median normalized features extracted from cellular images. Bar-
asertib and Cycloheximide compounds are colored by concentra-
tion demonstrating opposite phenotypic directions in PC space
producing opposite nuclear phenotypes. Images show nuclei im-
aged with Hoechst, scale bars: 20 mm. PC, principal component.
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were selected to represent 12 pairs of well-characterized
mechanistic subclasses, 21 of these compounds elicited robust
morphological changes in all eight cell lines.
To identify and quantify differential phenotypic responses,
the difference between theta values was calculated for all pairs
of cell lines, constrained to the maximum dissimilarity value of
180 and plotted as a heat map for each of the 21 compounds
(Fig. 4). Compounds with high theta values indicate a differ-
ential response between pairs of cell lines for that particular
compound. A representative image between KPL4 and MCF7
cells treated with 1mM of the topoisomerase I inhibitor SN38 is
an example of a compound that
induces a distinct phenotypic re-
sponse between these cell types
(TCCS=179), relative to the neg-
ative control for each cell line
(Fig. 4). The majority of cell line
comparisons returned low TCCS
values, indicating that most of the
breast cancer cell lines selected
respond similarly to the com-
pounds in our panel (Supplemen-
tary Fig. S1).
Differential Response of Breast
Cancer Cell Lines Are Stratified
by Molecular Subclass
To demonstrate the ability of the
TCCS method to cluster high-
content phenotypic response across
breast cancer subtypes with a
view to informing disease posi-
tioning and personalized medi-
cine strategies, we used data from
an exemplar molecular targeted
therapy, the dual Src/Abl inhibi-
tor Saracatinib (AZD0530).
To utilize the data present across
multiple titrations, the mean PCs
were taken across eight concen-
trations to create the 2D vector
with which the difference between
TCCS values across all pairs of cell
lines is calculated. TCCS values are
plotted as a heat map clustered by
hierarchical clustering using Eu-
clidean distance (Fig. 5A). This
revealed that the divergent high-
content phenotypic response in-
duced by Saracatinib across the breast cancer cell panel
clustered together based on their molecular subclass. Figure 5B
shows images of three cell lines treated with either DMSO
negative control or 1mMSaracatinib. FromFigure 5A theMDA-
MB-231 cell lines are found to have responded differently to
KPL4 and SKBR3 cell lines, which in turn elicited a similar
response to one another. This can be seen predominantly
through increased cell–cell contact in the Saracatinib-treated
MDA-MB-231 cells compared to the other two cell lines, ob-
served as an increase in normalized number of adjacent cells in
MDA-MB-231 cells (Supplementary Fig. S2). Although far from
Fig. 3. Circular histograms of theta values. (A) Circular histogram of theta values of Barasertib
calculated for all eight cell lines. (B) Phenotypic direction of cell lines treated with Barasertib
stratified by cell line. (C) A diagrammatic explanation of the theta value showing the difference in
theta values between HCC1569 and MDA-MB-231 cell lines treated with Barasertib.
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representative of all compound responses and disease subtypes,
this example does indicate the potential of high-content cell-
based phenotypic screening combined with application of the
TCCS method across genetically defined cell panels to provide
patient stratification hypothesis for both well-characterized
candidate drugs or poorly characterized active compounds
identified from phenotypic screens.
DISCUSSION
The rapid evolution and convergence of new technologies,
including advances in image-based high-content phenotypic
screening, induced pluripotent
stem cell (iPSC) technologies,
and gene editing, are well placed
to advance a new era of modern
phenotypic screening in more
informative and disease rele-
vant cell-based models of dis-
ease.15,29,30 However, a limitation
of phenotypic screening is the
identification of hit molecules or
candidate drugs without knowl-
edge of the target mechanism.
The lack of information on tar-
getmechanism,while not required
for drug approval, impedes the
design of personalized healthcare
strategies to combat disease het-
erogeneity. Several target decon-
volution strategies have been
applied to compounds discovered
by phenotypic screening to elu-
cidate target mechanisms.31–33
However, no target deconvolution
method is conclusive, and such
strategies are often based upon the
assumptions that a compoundwill
only inhibit a single target and
monitoring the activity and inhi-
bition of the elucidated target will
guide personalized therapy.
For the majority of compounds
discovered by phenotypic screens,
and for many complex human
diseases where the one-drug-one-
target hypothesis is unrealistic,
new nontarget-centric approaches
are required to understand drug
mechanism-of-action and guide
personalized healthcare strategies. In vitro pharmacogenomic or
pharmacoproteomic profiling across well-characterized cell
panels, representing specific disease subtypes, exemplifies one
approach for informing drugmechanism-of-action and guiding
personalized healthcare strategies in the absence of target
knowledge. Breast cancer is separated into fourmajormolecular
subtypes; Luminal A (ER-positive and/or progesterone receptor
(PR)-positive and HER2-negative and Low Ki67); Luminal B
(ER-positive and/or PR-positive and HER2-positive or HER2-
negative with high Ki67); Triple negative/basal like (ER- PR-
and Her2-negative); and HER2 type (ER- PR- negative and
Fig. 4. Heat map of theta values between pairs of cell lines for separate compounds. (A) Differ-
ence in theta values calculated between pairs of cell lines treated with 21 compounds at 1mM
concentration. Images show differential response between KPL4 and MCF7 cell lines treated with
1mM SN38. MCF7 cells are observed to decrease in cell area, with bright staining for the endo-
plasmic reticulum, whereas the KPL4 cells produce a ‘‘fried egg’’ morphology with large spread
cells and weak endoplasmic reticulum staining. Channels used are as follows: Red—MitoTracker
DeepRed (mitochondria); Green—Concanavalin A (endoplasmic reticulum); Blue—Hoechst33342
(nuclei). Scale bar: 100mm. (B) Circular histogram of theta values calculated for MCF7 and KPL4
cells treated with 1 mM SN38.
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Her2-positive). Each major molecular subtype of breast cancer
can be further divided into subclasses based upon genetic mu-
tation status and protein profiles, and the diagnosis of breast
cancer subtype dictates the most appropriate personalized
treatment for patients.34–36
In this article, we have developed a multiparametric high-
content assay, data visualization tools, and a TCCS method,
which support phenotypic screening of compound libraries
across genetically distinct cells representing known molecular
subtypes of disease. We provide proof-of-principle data applied
to eight breast cancer cells representing four disease subclasses
(Table 1), demonstrating the application of the method for
quantifying distinct phenotypic response between cell types and
clustering of cell-associated clinical subtypes based on similar
or dissimilar phenotypic response to compound treatment.
As previously discussed, several multiparametric pathway
and phenotypic profiling methods have been developed to
classify drug mechanism-of-action and uncover new drug–
target associations, and structure activity relationships in a
more holistic and unbiased manner.18,20–25,27 However, the
majority of these methods have been applied to single cell types
amenable to high-content imaging or large-scale biochemical
andproteomic analysis.18,21–25,27 The TCCSmethoddescribed in
this article was developed to provide a practical method to
enable comparativemultiparametric phenotypic analysis across
a panel of genetically distinct cell types, which provides rapid
quantification and visualization of divergent compound-
induced phenotypic response between cell types. An intuitive
explanation of the TCCSmethodwould be the cosine distance in
degrees of vectors in the first two
PCs; this is a variation on existing
methods that largely rely on corre-
lation or Euclidean distance be-
tween compound vectors.18
The benefits of the TCCS over
previous methods are as follows: (1)
use of distance from the negative
control to remove poorly active or
inactive compounds that might
produce spurious differences in cor-
relation of cosine similarity mea-
sures; (2) The comparison of each
data point to a common reference
vector enables visualizations of a
single metric, which depicts the rel-
ative change in phenotypic response
induced by a compound (Fig. 3A).
The most critical aspect of com-
paring results between panels of
distinct cell lines regardless of downstream methods is during
the data preprocessing stage, which requires careful normal-
ization against the negative control values for each cell line to
remove inherent differences in cell line morphology. Thus, the
TCCS method represents a flexible approach with broad ap-
plicability to quantifying and visualizing distinct phenotypes
induced by a panel of compounds within a single cell type and/
or the response of a single compound across multiple cell types.
The TCCSmethod removes compounds from the algorithm that
are not sufficiently different from the negative control. While
this increases the robustness of the calculation, it also creates
the opportunity to miss compounds that possess differential
sensitivity between cell lines. This limitation of the method
arises where certain compounds that do not induce any mor-
phological change in one cell line may still perturb cellular
morphology in another cell line, thus any such compound
would subsequently be removed from the calculation due to
insufficient distance from the negative control centroid, despite
eliciting a genuine differential response between cell lines.
However, this limitation can be simply rectified by im-
plementing an initial preanalytical stage of the algorithm by
calculating the distance from DMSO for all compounds across
all cell lines to assign either as ‘‘active’’ or ‘‘inactive’’ phenotypic
responders. Differences in the activation state of all compounds
across all cell lines are recorded and the active compounds then
progress to TCCS analysis to quantify and visualize a distinct
phenotype response across cell lines.
The TCCS method as outlined in this article utilized only the
first two PCs produced from the PCA. These two variables
Fig. 5. Heat map and hierarchical clustering of cell lines treated with Saracatinib. (A) Heatmap
of TCCS values calculated between all pairs of cell lines treated with Saracatinib with hierarchical
clustering by complete linkage of the Euclidean distance. (B) Images demonstrating two similar
phenotypic responses—KPL4 and SKBR3—and the dissimilar phenotypic response of MDA-MB-
231 cell lines to 1 mM Saracatinib treatment. Channels used: Red—MitoTracker DeepRed (mito-
chondria); Green—Concanavalin A (endoplasmic reticulum); Blue—Hoechst33342 (nuclei). Scale
bar: 100 mm. TCCS, Theta Comparative Cell Scoring.
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explain most of the variance of data in low dimensional data
represented by majority of high-throughput high-content
screens, which typically measure only small numbers of fea-
tures.37 In such high-throughput compound screens, TCCS
applied to the first two PCs would be expected to provide a
single value describing the difference in response across dif-
ferent cell lines for active compounds. The method as applied
to the first two PCs in this article becomes less informative in
higher dimensional data sets as more PCs are required to de-
scribe the data. As the calculation to define the angle between
two vectors [Eq. (1)] uses the dot product of the two vectors, the
vectors are not limited to the first two PCs, and it is entirely
reasonable that they could contain any number of PCs.
Therefore, an alternative option would be to implement the
TCCS method on a number of PCs that satisfy a user-defined
proportion of variance within the data.
Comparison of high dimensional vectors against one an-
other rather than against a reference vector allows for direct
calculation of a theta value in high dimensional space, an
example workflow using the TCCS method applied to more
than two PCs is provided in the online R scripts (github.com/
swarchal/TCCS_paper) and is represented in the description of
the TCCS workflow (Fig. 6). The TCCS method may also be
applied to the normalized assay parameters rather than PCs as
also demonstrated in the supplementary R workflow (gi-
thub.com/swarchal/TCCS_paper). However, care should be
taken to ensure that potentially uninformative parameters are
not included in such analysis to avoid introduction of un-
necessary assay noise. Thus, the most optimal application of
the TCCS method can be appropriately tailored to each study
and nature of the underlying high-content data set.
Multiple concentrations are not often used in high-
throughput cell-based screening assays, despite providinguseful
information to detect off-target effects and can be thought of as
inherent replicates of individual compound data. A further ap-
proach to incorporate titration data into defining direction in PC
space would be to fit a linear model to each compound using
simple linear regression, forcing the y-intersect through 0.While
this would lose information pertaining to the distance from the
DMSO centroid at each concentration, it would provide infor-
mation regarding goodness of fit, and data may be excluded
from the TCCS analysis if they do not fit the linear model well or
used to indicate compounds with off-target effects at higher
concentrations. As the theta value is essentially a direction
in PC space, another useful addition would be to relate theta
back to the feature loadings that describe how the PCs were
constructed. This would return the phenotypic features that
best describe a certain direction in phenotypic space. However,
PCA contains negatively weighted features and somethods such
as nonnegative matrix factorization in which the feature load-
ings are all positive values, may be a potential avenue for this
improvement.
Another potential use of TCCS method is in assay quality
control (QC). For example, TCCS could be applied to the
Fig. 6. TCCS workflow. (A) Normalized numerical data. (B) PC analysis, negative control values colored in blue. (C) Centering of PC values
to the negative control centroid. (D) Calculation of distance from the origin to each data point, an activity cutoff is derived from the
standard deviation of the distance to the negative control values. (D.2) In two-dimensional space, a directional histogram can be created by
the angle of each vector against a reference vector. (E) Inactive compounds excluded based on distance from the origin. (F) Determining the
angle between compounds. (F.2) Visualization or clustering of compounds based on theta values.
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simultaneous evaluation of two positive controls known to
elicit robustly different morphologies (e.g., paclitaxel and
staurosporine) along with a negative control such as DMSO to
determine a theta value between the two positive controls. It
would be expected that the two positive controls would have
a theta value greater than a specified minimum. The variance
of theta values between two positive controls per plate could
therefore be used as a measure of biological assay variability
during assay development and screening campaigns.
Incorporating amultiparametric QCmetric that utilizes high-
content analysis across two positive controls provides increased
robustness and more unbiased assessment of monitoring
variation in cell behavior and assay variability over current
methods that use a single positive control analysis of a pre-
selected parameter. Other multivariate assay QC metrics typi-
cally build on the Z0-factor using supervised machine learning
techniques such as Fisher’s linear discriminant analysis (LDA)
to best separate the positive and negative controls.38 Although
more robust than single parametric analysis, a drawback of this
method is that LDA is often prone to overfitting in high di-
mensions, which may produce overoptimistic QC values when
processed to the Z0-factor calculation.
The convergence of new technologies, including next-
generation sequencing, high-throughput proteomics, iPSC
technology, and high-content phenotypic screening, is well
placed to advance the identification of predictive biomarkers
and personalized medicine approaches across a broader range
of disease types and therapeutic classes.15,29,30,39,40
Our study provides a broadly applicable approach for
quantifying distinct phenotypic response between genetically
distinct cells using high-content analysis coupled to a TCCS
scoring method. The TCCS method that we describe provides a
univariate metric that can be applied to any high-content
assay for quantifying and visualizing a diverse phenotypic
response between cell types. The TCCS metric provides a
univariate score of distinct phenotypic response on a scale of
0–180 (where 0 = similar and where 180 =most dissimilar),
which can be used for correlation with orthogonal genetic,
epigenetic, and proteomic datasets to support the identifica-
tion of biomarkers of drug phenotype and further elucidate
drug mechanism-of-action at genetic and pathway levels.
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Abbreviations Used
2D ¼ two dimensional
3D ¼ three dimensional
CCLE ¼ Cancer Cell Line Encyclopaedia
DAPI ¼ 4,6-diamidino-2-phenylindole
DMSO ¼ dimethyl sulfoxide
EC50 ¼ concentration of drug that produces a 50% maximal response
ER ¼ estrogen receptor
FITC ¼ fluorescein isothiocyanate
GI50 ¼ concentration of a drug that gives half-maximal inhibition
of cell proliferation
HER2 ¼ human epidermal growth factor receptor 2
iPSC ¼ induced pluripotent stem cell
LDA ¼ linear discriminant analysis
PBS ¼ phosphate-buffered saline
PC ¼ principal component
PCA ¼ principal component analysis
PFA ¼ paraformaldehyde
PI3K ¼ phosphoinositide 3-kinase
PR ¼ progesterone receptor
PTEN ¼ phosphatase and tensin homolog
QC ¼ quality control
TCCS ¼ Theta Comparative Cell Scoring
TN ¼ triple negative
WT ¼ wild type
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